ON-DEMAND WEBINAR

China’s generic drug industry undergoes an overhaul

Pharmaceutical industry’s response to new regulatory reforms and potential strategies for both domestic and MNC firms.

Karan Verma
Senior Analyst
Clarivate
Amardeep Singh
Senior Analyst
Clarivate

China’s $90 billion generic drug market is at the verge of a revolution, with the launch of national regulatory reforms that aim to centralize drug procurement and assure quality control in this highly fragmented and unregulated market. How will these reforms—the generic quality consistency evaluation (GQCE) process and the volume-based procurement (VBP) programs—assure patient-access to high-quality and cost-effective generic medicines in China?

In this webinar, we will discuss how China’s pharmaceutical market is responding to the early wave of these regulatory reforms and how the market is expected to emerge in the future with these reforms fully established.